EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer

Zhen Chen, Karin A Vallega, Dongsheng Wang, Elsa Bildtsen, Haian Fu, Suresh S Ramalingam, Andrey A Ivanov, Shi-Yong Sun

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.218010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Zhen Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Hematology and Medical Oncology and Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA,…. Hauptthemen laut MEDLINE: Aniline Compounds, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

c-Myc inhibition is a critical mechanism in mediating the therapeutic efficacy of osimertinib against EGFR mutant (EGFRm) NSCLCs and accordingly targeting c-Myc is an effective strategy for overcoming osimertinib acquired resistance, a challenging issue in the clinic. However, lack of specific c-Myc inhibitors restricts the application of this strategy. The current study focused on determining the potential application of an alternative c-Myc inhibitory approach to overcome osimertinib acquired resistance via targeting the MKK3/c-Myc interaction that stabilizes c-Myc protein. SGI-1027, as the first disruptor of MKK3/c-Myc interaction, effectively decreased c-Myc levels via disrupting this interaction and promoting c-Myc degradation in different osimertinib-resistant EGFRm NSCLC cell lines that possessed elevated levels of both c-Myc and MKK3 and increased MKK3/c-Myc interaction. The combination of osimertinib with SGI-1027 synergistically decreased the survival of osimertinib-resistant cells and enhanced apoptosis. Consistently, MKK3 knockdown caused c-Myc reduction and sensitized osimertinib-resistant cells to undergo apoptosis upon osimertinib treatment. Moreover, the SGI-1027 and osimertinib combination was significantly more active than either single agent in suppressing the growth of osimertinib-resistant tumors in mice. In sensitive EGFRm NSCLC cell lines, osimertinib inhibited MKK3 and c-Myc interaction with reduction of c-Myc levels, suggesting a critical mechanism by which osimertinib induces c-Myc degradation. Hence, our findings reveal molecular mechanisms accounting for c-Myc reduction by osimertinib in sensitive EGFRm NSCLC cells and c-Myc elevation in EGFRm NSCLC with acquired osimertinib resistance. Our results also suggest a novel strategy to target c-Myc via disrupting the MKK3/c-Myc interaction to overcome osimertinib acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsDrug Resistance, NeoplasmLung NeoplasmsAcrylamidesProto-Oncogene Proteins c-mycMAP Kinase Kinase 3Carcinoma, Non-Small-Cell LungIndolesHumansPyrimidinesAnimalsErbB ReceptorsCell Line, TumorMutationMiceXenograft Model Antitumor AssaysApoptosisProtein Kinase InhibitorsMice, Nude

Stichwörter der Autor:innen

Acquired resistanceMKK3 and lung cancerOsimertinibc-Myc

Substanzen

IndolesosimertinibAniline CompoundsPyrimidinesAcrylamidesErbB ReceptorsProto-Oncogene Proteins c-mycMAP Kinase Kinase 3EGFR protein, humanMYC protein, human

Autor:innen und Institutionen

  • Departments of Hematology and Medical Oncology and Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Pharmacology and Chemical Biology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Departments of Hematology and Medical Oncology and Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA. Electronic address: ssun@emory.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Chen, Z., Vallega, K. A., Wang, D., Bildtsen, E., Fu, H., Ramalingam, S. S., Ivanov, A. A., & Sun, S. Y. (2025). Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218010

Vancouver

Chen Z, Vallega KA, Wang D, Bildtsen E, Fu H, Ramalingam SS, et al. Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218010

BibTeX
@article{Chen2025,
  author = {Chen, Zhen and Vallega, Karin A and Wang, Dongsheng and Bildtsen, Elsa and Fu, Haian and Ramalingam, Suresh S and Ivanov, Andrey A and Sun, Shi-Yong},
  title = {Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.218010}
}
Kostenlos starten →